English
Spanish
French
Italian
German
NEWS
Latest News
HS Foundation Launches New HS Buddy Program to Support Clinical Trial Participants
July 29, 2025
The HS Buddy Program is a peer support initiative designed to connect individuals currently in or considering a clinical trial with experienced "buddies" who can offer guidance, share personal insights, and help navigate the clinical trial journey. Learn how you can get involved as a participant or a peer mentor.
Read more
From the Heart: July 2025
July 17, 2025
In this issue: We're celebrating 20 years of advancing care, research, and support for those impacted by Hidradenitis Suppurativa. Catch up on recent news in the HS world, important updates for SHSA 2024 (including early bird deadlines), new research opportunities, and ways to get involved in our growing community.
Read more
New Study Explores Tunnel-Targeted Antimicrobial Gel for HS Treatment
July 11, 2025
A newly published prospective study in JAAD highlights a novel approach for treating Hidradenitis Suppurativa using a topical clindamycin gel delivered directly into tunnels. The treatment showed promising results in reducing inflammation, resolving tunnels, restoring microbial balance, and improving quality of life. Led by researchers at the University of Miami, including HSF President Dr. Hadar Lev-Tov, this work offers new insights into localized therapies for HS.
Read more
Dermatologic Procedures for Hidradenitis Suppurativa
July 10, 2025
Explore how dermatologic procedures like deroofing, excision, and laser therapies are helping patients with hidradenitis suppurativa achieve better outcomes. This article highlights expert insights on selecting the right approach based on severity, recurrence, and patient goals.
Read more
Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa
July 2, 2025
A newly published living systematic review and network meta-analysis in JAMA Dermatology offers an in-depth look at the current evidence on medical therapies for HS. This important research helps inform treatment decisions and highlights the growing momentum in HS clinical trials.
Read more
Spironolactone for Hidradenitis Suppurativa: A Game-Changer for Women of Childbearing Age?
June 30, 2025
Could spironolactone be a game-changer for women with early-stage HS? A recent study found that while only 1 in 5 women of childbearing age saw improvement with the hormone-blocking drug, those with milder disease and earlier treatment were far more likely to benefit. This research offers valuable insight into tailoring HS treatment for patients most likely to respond.
Read more
Deroofing – Safe and Effective for HS Patients
June 18, 2025
A new study highlights the safety and effectiveness of deroofing—a surgical treatment for hidradenitis suppurativa. Among 44 patients, only 12% of lesions returned within a year, and most reported less pain and better quality of life. While further research is needed, these results suggest deroofing may be a valuable option, even alongside systemic therapies.
Read more
Semaglutide for diabetes, weight loss, and… Hidradenitis Suppurativa?
April 28, 2025
Could a popular weight loss and diabetes drug also help treat hidradenitis suppurativa? See what researchers discovered about semaglutide’s surprising potential.
Read more
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppura
March 18, 2025
Incyte announced positive Phase 3 results for povorcitinib in hidradenitis suppurativa, with both trials meeting their primary endpoint of reducing inflammatory nodules.
Read more
2025 Danby Research Grant Recipients
March 7, 2025
From machine learning and gene expression to fibroblast signaling and pain pathways, this year’s Danby grantees are advancing bold new investigations into the biology and complexity of Hidradenitis Suppurativa.
Read more